Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in patients with triple-class–exposed, relapsed/refractory multiple myeloma, highlighting an analysis of cytopenias and infections in patients from the phase 3 KarMMa-3 trial.
Watch Dr. Ariel F. Grajales-Cruz, from Moffitt Cancer Center, discuss updates in MGUS and smoldering disease during the CURE Educated Patient Multiple Myeloma Summit.